HK1201150A1 - Scheme for administering n-hydroxy-4-2-[3-(n,n- dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxybenzamide n--4-2-[3-(n,n-)-2-] - Google Patents

Scheme for administering n-hydroxy-4-2-[3-(n,n- dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxybenzamide n--4-2-[3-(n,n-)-2-]

Info

Publication number
HK1201150A1
HK1201150A1 HK14112851.7A HK14112851A HK1201150A1 HK 1201150 A1 HK1201150 A1 HK 1201150A1 HK 14112851 A HK14112851 A HK 14112851A HK 1201150 A1 HK1201150 A1 HK 1201150A1
Authority
HK
Hong Kong
Prior art keywords
ethoxybenzamide
ylcarbonylamino
dimethylaminomethyl
benzofuran
administering
Prior art date
Application number
HK14112851.7A
Other languages
English (en)
Chinese (zh)
Inventor
Ioana Kloos
Renata Robert
Anne Jacquet-Bescond
Stphane Depil
Marylore Chenel
Sylvain Fouliard
Sriram Balasubramanian
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of HK1201150A1 publication Critical patent/HK1201150A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK14112851.7A 2011-09-08 2014-12-23 Scheme for administering n-hydroxy-4-2-[3-(n,n- dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxybenzamide n--4-2-[3-(n,n-)-2-] HK1201150A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161573585P 2011-09-08 2011-09-08
FR1102727 2011-09-08
PCT/FR2012/052004 WO2013034863A1 (fr) 2011-09-08 2012-09-07 Schema d'administration du n- hydroxy - 4 - {2- [3- (n, n- dimethylaminomethyl) benzofuran- 2 - ylcarbonylamino] ethoxy} benzamide

Publications (1)

Publication Number Publication Date
HK1201150A1 true HK1201150A1 (en) 2015-08-28

Family

ID=47830027

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112851.7A HK1201150A1 (en) 2011-09-08 2014-12-23 Scheme for administering n-hydroxy-4-2-[3-(n,n- dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxybenzamide n--4-2-[3-(n,n-)-2-]

Country Status (17)

Country Link
US (2) US8883199B2 (xx)
EP (1) EP2753322B1 (xx)
JP (1) JP6014142B2 (xx)
KR (1) KR20140073521A (xx)
CN (1) CN103889409A (xx)
AR (1) AR087803A1 (xx)
AU (2) AU2012306122A1 (xx)
CA (1) CA2847011A1 (xx)
HK (1) HK1201150A1 (xx)
MX (1) MX2014002663A (xx)
RU (1) RU2600793C2 (xx)
SG (2) SG11201400120UA (xx)
TW (1) TWI544920B (xx)
UA (1) UA113634C2 (xx)
UY (1) UY34295A (xx)
WO (1) WO2013034863A1 (xx)
ZA (1) ZA201401710B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092115A2 (en) 2003-04-07 2004-10-28 Axys Pharmaceuticals Inc. Hydroxamates as therapeutic agents
DK2099442T3 (en) * 2006-12-26 2015-02-16 Pharmacyclics Inc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
NZ579048A (en) * 2007-01-30 2012-05-25 Pharmacyclics Inc Methods for determining cancer resistance to histone deacetylase inhibitors
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
US9492423B2 (en) 2011-09-13 2016-11-15 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
EP3027192A4 (en) 2013-08-02 2017-03-22 Pharmacyclics, LLC Methods for the treatment of solid tumors
KR101684854B1 (ko) * 2016-06-13 2016-12-09 아이오틴 주식회사 보호자 알림기능을 이용한 휴대용 스마트약통 및 이를 포함하는 복용시간 알림시스템
CN114146181B (zh) * 2021-10-29 2022-09-09 徐诺药业(南京)有限公司 含Pan-HDAC和免疫检查点抑制剂的组合及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1489078E (pt) * 2002-03-28 2010-02-24 Mitsubishi Tanabe Pharma Corp Derivados de benzofurano
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
WO2004092115A2 (en) * 2003-04-07 2004-10-28 Axys Pharmaceuticals Inc. Hydroxamates as therapeutic agents
EP1874324A1 (en) * 2005-04-21 2008-01-09 Alza Corporation Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes

Also Published As

Publication number Publication date
JP2014526457A (ja) 2014-10-06
US20150024040A1 (en) 2015-01-22
US8883199B2 (en) 2014-11-11
AU2016202594B2 (en) 2017-09-14
US20130064880A1 (en) 2013-03-14
TWI544920B (zh) 2016-08-11
AR087803A1 (es) 2014-04-16
AU2016202594A1 (en) 2016-05-19
UA113634C2 (xx) 2017-02-27
SG11201400120UA (en) 2014-09-26
JP6014142B2 (ja) 2016-10-25
WO2013034863A1 (fr) 2013-03-14
CN103889409A (zh) 2014-06-25
CA2847011A1 (fr) 2013-03-14
NZ622112A (en) 2016-07-29
RU2600793C2 (ru) 2016-10-27
EP2753322A1 (fr) 2014-07-16
AU2012306122A1 (en) 2014-03-13
TW201313228A (zh) 2013-04-01
UY34295A (es) 2013-04-30
EP2753322B1 (fr) 2016-08-03
MX2014002663A (es) 2014-08-29
SG10201505619QA (en) 2015-08-28
KR20140073521A (ko) 2014-06-16
RU2014113399A (ru) 2015-10-20
ZA201401710B (en) 2015-01-28

Similar Documents

Publication Publication Date Title
IL251744A0 (en) Anti-il-6 receptor antibody variants, compositions comprising the same and uses thereof
HK1193091A1 (en) Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3- en-2-ones for therapy 3-(-3-)-88--4--1-[45]-3--2-
ZA201307119B (en) Double-acylated glp-1 derivatives
HK1181139A1 (zh) 用於社交摘要的可適配佈局
EP2762476A4 (en) 1,2,4-triazine-6-carboxamide derivative
GB201216143D0 (en) .
EP2699091A4 (en) 2 ', 6'-dioxo-3'-deutero-PIPERIDIN-3-YL-isoindoline COMPOUNDS
GB201718998D0 (en) Integrated, extendable anesthesia system
EP2989319A4 (en) HYDRO-MOTOR MACHINE
HK1201150A1 (en) Scheme for administering n-hydroxy-4-2-[3-(n,n- dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxybenzamide n--4-2-[3-(n,n-)-2-]
HK1202288A1 (en) 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives 2---35-
HK1198586A1 (zh) -二氟甲基- -二氫- 噁嗪- -胺衍生物
GB201203412D0 (en) .
HK1192757A1 (zh) 取代的 -芳基- -苯基- -三嗪- -胺
GB201203063D0 (en) .
IL227544B (en) (r)- Leoplomide, a method for its preparation and its medical uses
EP2672024A4 (en) Operating machine
HK1191942A1 (zh) 新型六氫環戊二烯並吡咯酮,六氫吡咯並吡咯酮,八氫吡咯並吡啶酮和八氫吡啶酮化合物
GB201106260D0 (en) Forced induction for i.c. engines
IL232630A0 (en) A method for the preparation of 6,2-difluoroacetophenones
GB2510513B (en) Integrated, extendable anesthesia system
AU2011900916A0 (en) Garment for ostymates
GB201115337D0 (en) Seasontickethub.com
GB201110324D0 (en) Estreettalk.com
GB201105651D0 (en) S.f.i.